Test Kits for Human Kidney Damage

Millipore Corporation introduced new MILLIPLEX® Multi-Analyte Profile (MAP) human kidney toxicity assay kits, the first commercially available multiplex kits for human drug toxicity research.

Kidney toxicity, also known as nephrotoxicity, is one of the leading reasons that drug candidates fail to advance through the development pipeline. Traditional tests for serum creatinine and blood urea nitrogen (BUN) can only detect kidney damage at later stages, after significant injury has occurred. In addition, these tests must often be combined with histopathological examination to verify the location of damage in the kidney.

New MILLIPLEX MAP kits allow researchers to screen for biomarkers that may indicate the kidney is undergoing toxic insult. Each renal protein biomarker is associated with localisations in the kidney that can indicate the type of damage that is occurring. The kits include biomarkers that are recognised by the United States Food and Drug Administration (U.S. FDA) and the European Medicines Agency (EMEA) to provide additional and complementary information to the currently available standards and can be used to gather further data in monitoring drug-induced renal toxicity in humans.

The multi-analyte kits are available for testing either serum or urine using proven Luminex® xMAP® technology. These kits are available in magnetic bead and traditional (polystyrene) bead formats and can be utilised with all Luminex platforms.